Oruka Therapeutics, Inc.

NASDAQ:ORKA

Biotechnology

Healthcare
$95.74 +0.65%

+$0.46 today

Market cap
$6.49B
Beta
-0.30
P/E (TTM)
-33.9
EPS (TTM)
-$2.11
52W Low $10.77High $91.00

Volume 0.52M

Average 1.55M

ORKA Net Income

Bottom-line profit after all expenses, interest, and taxes.

Oruka Therapeutics, Inc.NASDAQ: ORKA

Net Income · Q3 FY2026 · quarter ended Sep 2026

Net income remains negative

Q3 FY2026 net income was -$49.97M, compared with -$30.28M a year earlier. Trailing-twelve-month net income was -$152.57M.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate of -$98.71M (+6.4%) for the fiscal year ending Dec 2026, a step up from the -25.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$49.97M-21.3% QoQ
Last fiscal yearDec 2025
-$105.43M-25.9% YoY
LTMSep 2026
-$152.57M-39.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-65.0%-2.4%+62.6 pp
1 year-25.9%+6.4%+32.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(105.43M) USD
Year-over-year change
-25.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ORKA compares with its peers on the latest reported figures

  • ORKA's LTM Sep 2026 net income of -$152.57M is the 7th highest of the 10 companies compared; the peer median is -$69.66M.
  • Its year-over-year change of -39.7% is the 6th highest of 10, against a peer median of -31.1%.
ORKA Competitors Peer median
Net Income for ORKA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026-$26.79M +81.0%—11.5%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-$29.91M +73.9%—1570.9%
CNTBConnect Biopharma Holdings LimitedFY2025-$55.48M -255.0%—86687.5%
ATTOAttovia Therapeutics, Inc.FY2025-$60.63M -52.3%—4490.9%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$69.66M +46.5%—832.6%
ZURAZura Bio LimitedLTM Mar 2026-$75.43M -31.1%——
ORKAOruka Therapeutics, Inc.LTM Sep 2026-$152.57M -39.7%——
XNCRXencor, Inc.LTM Jun 2026-$163.33M +8.8%—155.6%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026-$257.08M -77.0%——
ALMSAlumis Inc. Common StockLTM Jun 2026-$438.96M -92.9%—5933.5%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ORKA) -$69.66M-31.1%—1570.9%

Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue91K114K111K27K83K
Gross Profit(91K)(114K)(111K)(27K)(83K)
Gross Margin—————
Research & Development13.83M4.46M1.01M75.06M100.64M
Selling, General & Admin5.41M5.26M6.17M13.04M21.33M
Operating Expenses19.24M9.73M7.19M88.1M121.97M
Depreciation & Amortization91K114K111K27K83K
EBITDA(19.23M)(9.81M)(5.23M)(82.23M)(105.35M)
EBITDA Margin—————
Operating Income(19.34M)(9.84M)(7.3M)(88.12M)(122.05M)
Operating Margin—————
Interest Income0675K1.96M5.86M16.63M
Interest Expense0001.47M0
Other Income / Expenses13K(85K)1.96M4.4M16.62M
Income Before Tax(19.32M)(9.93M)(5.34M)(83.72M)(105.43M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(19.32M)(9.93M)(5.34M)(83.72M)(105.43M)
Net Margin—————
EPS (Basic)(16.68)(8.27)(4.44)(4.99)(2.31)
EPS (Diluted)(16.68)(8.27)(4.44)(4.99)(2.31)
Weighted Avg Shares13.9M14.41M14.42M16.79M45.61M
Weighted Avg Shares (Diluted)13.9M14.41M14.42M16.79M45.61M

Oruka Therapeutics, Inc.

NASDAQ:ORKA

Intrinsic Alpha fair value

Locked

Current Price

$95.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.